Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Peroxisome proliferator-activated receptor gamma is required for the inhibitory effect of ciglitazone but not 15-deoxy-Delta 12,14-prostaglandin J2 on the NFkappaB pathway in human endothelial cells.

Authors: Kaplan, Jennifer; Cook, James A; O'Connor, Michael; Zingarelli, Basilia

Published In Shock, (2007 Dec)

Abstract: Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-activated nuclear receptor with effects on inflammation, atherosclerosis, and apoptosis. The endogenous PPARgamma ligand, 15-deoxy-Delta12,14-PGJ2 (15d-PGJ2), and the synthetic ligand, ciglitazone, have anti-inflammatory properties in endothelial cells. In addition to PPARgamma-dependent effects on the anti-inflammatory process, it has been proposed that PPARgamma ligands may also inhibit the nuclear transcription factor kappaB (NFkappaB) pathway in a PPARgamma-independent manner. The purpose of this study was to compare the effects of 15d-PGJ2 and ciglitazone on the cytokine-induced activation of the NFkappaB pathway. Human umbilical vein endothelial cells (HUVECs) were transiently transfected with NFkappaB-luciferase or PPARgamma elements-luciferase reporter constructs for 48 h. The HUVECs were pretreated with 15d-PGJ2 or ciglitazone (30 microM) for 1 h, followed by a 4-h stimulation with tumor necrosis factor alpha (100 U/mL). Luciferase assay was performed to determine reporter activity. Additionally, HUVECs were transiently transfected with a dominant-negative mutant, which retains ligand and DNA binding but exhibits markedly reduced transactivation. Stimulation of HUVEC with tumor necrosis factor alpha increased NFkappaB activation while decreasing PPARgamma activity. Overexpression of a dominant-negative PPARgamma mutant prevented the inhibitory effect of ciglitazone on cytokine-induced NFkappaB activation in transfected human endothelial cells. Conversely, 15d-PGJ2 inhibited the cytokine-induced NFkappaB activation even in the absence of PPARgamma. Our data suggest that 15d-PGJ2 exerts direct inhibitory effects on the NFkappaB pathway through a PPARgamma-independent mechanism. On the contrary, the inhibitory effect of ciglitazone on the NFkappaB pathway seems to require PPARgamma activation.

PubMed ID: 17621259 Exiting the NIEHS site

MeSH Terms: Cells, Cultured; Cyclooxygenase 2/metabolism; Dose-Response Relationship, Drug; E-Selectin/metabolism; Endothelial Cells/cytology; Endothelial Cells/drug effects*; Endothelial Cells/metabolism; Enzyme-Linked Immunosorbent Assay; Humans; Intercellular Adhesion Molecule-1/metabolism; Luciferases/genetics; Luciferases/metabolism; Mutation; NF-kappa B/genetics; NF-kappa B/metabolism*; PPAR gamma/genetics; PPAR gamma/metabolism*; Prostaglandin D2/analogs & derivatives*; Prostaglandin D2/pharmacology; Recombinant Fusion Proteins/genetics; Recombinant Fusion Proteins/metabolism; Signal Transduction/drug effects; Thiazolidinediones/pharmacology*; Transfection; Tumor Necrosis Factor-alpha/pharmacology; Vascular Cell Adhesion Molecule-1/metabolism

to Top